ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Bought by Covestor Ltd

Covestor Ltd grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 7,038.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,996 shares of the biotechnology company’s stock after acquiring an additional 5,912 shares during the quarter. Covestor Ltd’s holdings in ADMA Biologics were worth $103,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ADMA. Perpetual Ltd acquired a new stake in ADMA Biologics during the fourth quarter worth about $62,300,000. Lord Abbett & CO. LLC purchased a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $61,858,000. Allspring Global Investments Holdings LLC increased its holdings in shares of ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after buying an additional 2,613,482 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at approximately $19,076,000. Finally, Principal Financial Group Inc. lifted its holdings in ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after acquiring an additional 1,059,394 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA opened at $19.40 on Friday. The firm has a 50-day simple moving average of $17.78 and a two-hundred day simple moving average of $18.16. The stock has a market cap of $4.59 billion, a PE ratio of 69.29 and a beta of 0.53. ADMA Biologics, Inc. has a 1-year low of $5.91 and a 1-year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.